Drug Price Trends for NUPLAZID

Average Pharmacy Cost for NUPLAZID

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
NUPLAZID 34 MG CAPSULE	63090-0340-30	170.49600	EACH	2026-03-18
NUPLAZID 34 MG CAPSULE	63090-0340-30	170.49600	EACH	2026-02-18
NUPLAZID 34 MG CAPSULE	63090-0340-30	170.49600	EACH	2025-12-17

Best Wholesale Price for NUPLAZID

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
NUPLAZID 34MG CAP	Acadia Pharmaceuticals	63090-0340-30	30	3329.11	110.97033	EACH	2024-01-01 - 2028-09-30	Big4
NUPLAZID 10MG TAB	Acadia Pharmaceuticals	63090-0100-30	30	2999.96	99.99867	EACH	2023-10-01 - 2028-09-30	Big4
NUPLAZID 34MG CAP	Acadia Pharmaceuticals	63090-0340-30	30	4914.78	163.82600	EACH	2024-01-01 - 2028-09-30	FSS
NUPLAZID 10MG TAB	Acadia Pharmaceuticals	63090-0100-30	30	4496.23	149.87433	EACH	2023-10-01 - 2028-09-30	FSS
NUPLAZID 10MG TAB	Acadia Pharmaceuticals	63090-0100-30	30	3369.12	112.30400	EACH	2024-01-01 - 2028-09-30	Big4

NUPLAZID (Pimavanserin) Market Analysis and Price Projections

Last updated: February 19, 2026

NUPLAZID (pimavanserin) is a selective serotonin 5-HT2A receptor inverse agonist and antagonist. Its primary indication is the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). The drug is developed by Acadia Pharmaceuticals.

What is the current market size and growth trajectory for NUPLAZID?

The market for NUPLAZID is driven by the prevalence of Parkinson's disease and the specific unmet need for treating psychosis in this patient population. Parkinson's disease affects an estimated 1 million people in the U.S., and approximately 40% of these individuals will develop Parkinson's disease psychosis (PDP) [1]. Globally, the prevalence of Parkinson's disease is estimated to be around 6.1 million people [2].

NUPLAZID was launched in 2016. While specific market size figures for NUPLAZID are not publicly disclosed by Acadia Pharmaceuticals, industry estimates and revenue reports provide insight into its market penetration. In 2022, Acadia Pharmaceuticals reported net product sales of NUPLAZID of approximately $927 million [3]. This represents a significant increase from prior years, indicating consistent market growth. For instance, net sales in 2021 were $833 million, and in 2020, they were $666 million [3]. This trajectory suggests a compound annual growth rate (CAGR) in the mid-to-high single digits in recent years.

The growth is attributed to the drug's established efficacy and safety profile for PDP, along with ongoing efforts by Acadia to expand its label. The potential for expanded indications in areas like dementia-related psychosis (DRP) is a significant factor in future growth projections.

What are the key drivers and challenges impacting NUPLAZID's market performance?

Key Market Drivers:

• Increasing Parkinson's Disease Prevalence: As the global population ages, the incidence of neurodegenerative diseases like Parkinson's disease is expected to rise, directly increasing the pool of potential NUPLAZID patients.
• Unmet Need in PDP: NUPLAZID is the first and only FDA-approved medication specifically for PDP. Prior to its approval, treatment options were limited and often exacerbated motor symptoms of Parkinson's disease.
• Label Expansion Opportunities: Acadia Pharmaceuticals is actively pursuing expanded indications for NUPLAZID, most notably for dementia-related psychosis (DRP), including Alzheimer's disease psychosis (ADP) and other forms of dementia-associated psychosis. Successful approval in these larger patient populations would represent a substantial market expansion.
• Physician and Patient Awareness: Growing awareness among neurologists, geriatricians, psychiatrists, and caregivers regarding NUPLAZID's benefits contributes to its prescription volume.
• Branded Drug Market Dynamics: In the U.S. pharmaceutical market, branded drugs for chronic conditions often maintain pricing power and market share due to patent protection and physician familiarity.

Key Market Challenges:

• Competition: While NUPLAZID is the only drug approved for PDP, off-label use of other antipsychotics remains a challenge. Furthermore, the potential for new entrants or improved therapies in DRP could emerge.
• Pricing and Reimbursement: The drug's price point, typical for novel branded therapeutics, can present challenges in terms of patient access and payer coverage, particularly in international markets.
• Patent Expirations and Generic Entry: Acadia's patents for NUPLAZID will eventually expire, opening the door for generic competition. The timing and strength of these patents are critical for long-term revenue.
• Clinical Trial Outcomes for Label Expansion: The success of ongoing clinical trials for expanded indications, particularly for DRP, is crucial. Any failures or delays in these trials could significantly impact future market growth projections.
• Physician Prescribing Habits: Shifting established prescribing habits for managing psychosis in the elderly can be a slow process.

What is the current pricing structure and typical reimbursement landscape for NUPLAZID?

NUPLAZID is a prescription medication available in oral capsule and tablet forms, as well as an oral suspension for patients with swallowing difficulties. The pricing is set by Acadia Pharmaceuticals.

List Price: The manufacturer's list price (WAC - Wholesale Acquisition Cost) for NUPLAZID varies by dosage and formulation. As of late 2023, for example, a 30-day supply of NUPLAZID 34mg capsules can range from approximately $1,000 to $1,300 USD, depending on the pharmacy and dispensing fees [4]. The 10mg tablets are similarly priced on a per-day basis.

Net Price and Discounts: The actual net price realized by Acadia is lower than the WAC due to various rebates, discounts, and chargebacks provided to pharmacy benefit managers (PBMs), wholesalers, and payers.

Reimbursement Landscape:

• Commercial Insurance: NUPLAZID is generally covered by most major commercial insurance plans in the U.S. However, coverage can be subject to prior authorization requirements, step-therapy protocols, and specific formulary placement. Many plans require prior authorization to ensure the patient meets the criteria for Parkinson's disease psychosis.
• Medicare and Medicaid:
  • Medicare Part D: NUPLAZID is covered by Medicare Part D plans. It typically falls within higher formulary tiers (e.g., Tier 3 or 4), meaning patients may face higher co-pays or coinsurance. Beneficiaries with the Medicare Extra Help program may have reduced out-of-pocket costs.
  • Medicaid: Coverage varies by state, but NUPLAZID is generally covered by state Medicaid programs, often with prior authorization requirements.
• Patient Assistance Programs: Acadia Pharmaceuticals offers patient assistance programs, such as the NUPLAZID Patient Assistance Program, to help eligible uninsured or underinsured patients afford their medication.

International Markets: Pricing and reimbursement vary significantly by country. In regions with price controls or national health systems, the price of NUPLAZID is often negotiated and may be substantially lower than in the U.S. market.

What are the projected price trends for NUPLAZID in the next 5-10 years?

Projecting pharmaceutical prices is complex, influenced by multiple factors including patent status, competitive landscape, regulatory environment, and payer negotiations.

Short-Term (1-3 Years):

• Stable to Modest Increases: Given its patent protection for PDP and the ongoing expansion efforts, NUPLAZID's price in the U.S. is likely to remain relatively stable with modest annual increases, reflecting general pharmaceutical inflation and continued market demand. Acadia may implement price increases in the range of 5-8% annually, consistent with industry norms.
• Impact of DRP Label Expansion (if successful): If NUPLAZID receives approval for DRP, this could reinforce its market position and potentially support continued pricing power, although payer pressure on broader DRP treatments might moderate aggressive price hikes.

Mid-Term (3-7 Years):

• Patent Expiration Horizon: As U.S. patents for NUPLAZID begin to approach their expiration dates (primary patents are generally understood to extend into the late 2020s and early 2030s, though specific expiration dates and their scope are complex and subject to litigation), the threat of generic entry becomes more significant.
• Price Erosion Pressure: Anticipation of generic competition or the actual introduction of generics will typically lead to significant price erosion for the branded product. For branded drugs, generic entry can result in price drops of 50-85% within the first year of generic availability.
• Continued DRP Market Share: If NUPLAZID maintains a strong market share in DRP indications post-PDP, this will provide a baseline revenue stream, but pricing will be significantly more competitive.

Long-Term (7-10 Years):

• Significant Price Decline Due to Generics: By this period, if generic versions are available and widely adopted, the price of NUPLAZID (or its generic equivalent) will likely have fallen dramatically. The market will then be characterized by volume-based sales and competition among multiple generic manufacturers.
• Niche Market Pricing: The drug may continue to be used, but at a substantially lower price point reflective of generic competition. Pricing would be driven by manufacturing costs and payer reimbursement policies for generic antipsychotics.

Key Factors Influencing Future Pricing:

• Patent Durability: The exact expiration dates and enforceability of all patents covering NUPLAZID are critical. Any patent challenges or extensions will directly impact the timeline for generic entry.
• Success of DRP Indication: Positive outcomes and FDA approval for DRP would solidify NUPLAZID's market position and potentially delay aggressive price reductions by maintaining significant sales volume.
• Payer Negotiations and Value-Based Pricing: Payers will continue to exert pressure on pricing. The perception of NUPLAZID's value, particularly in broader indications like DRP, will influence reimbursement levels.
• Emergence of Novel Competitors: Development of entirely new therapeutic classes for PDP or DRP could disrupt the market and further influence pricing dynamics.

Summary of Price Projection Trends:

• Current-to-3 Years: Stable with modest annual increases (5-8%).
• 3-7 Years: Increasing pressure as patent expiration nears; potential for initial price stabilization if DRP indication is secured, followed by anticipatory price erosion.
• 7-10 Years: Significant price decline (50-85% or more) due to generic competition.

What are the key intellectual property (IP) considerations and their impact on NUPLAZID's market exclusivity?

Acadia Pharmaceuticals holds a portfolio of patents protecting NUPLAZID (pimavanserin). The strength and longevity of these patents are central to the drug's market exclusivity and pricing power.

Key Patents and Exclusivity Periods:

• Composition of Matter Patents: These are typically the strongest patents, protecting the molecule itself. The original composition of matter patent for pimavanserin has largely expired or is nearing expiration.
• Method of Use Patents: Acadia has secured patents covering the use of pimavanserin for specific indications, most notably Parkinson's disease psychosis. These patents are critical for maintaining exclusivity for its approved uses.
  • The primary method of use patent related to PDP treatment is generally understood to expire in the late 2020s, with potential for extensions.
• Formulation and Manufacturing Patents: Additional patents may cover specific formulations (e.g., extended-release) or manufacturing processes, which can extend market exclusivity beyond the expiration of composition of matter patents.
• Orphan Drug Exclusivity: In the U.S., NUPLAZID received 7 years of Orphan Drug Exclusivity for PDP, as Parkinson's disease psychosis is considered a rare disease. This exclusivity is separate from patent protection.
• Pediatric Exclusivity: Acadia has also obtained 6 months of pediatric exclusivity in the U.S. through studies conducted in pediatric populations, which extends exclusivity by six months from the expiration of the underlying patent or exclusivity.

Patent Litigation and Challenges:

• Generic Challenges: As NUPLAZID's market exclusivity periods approach their end, it is common for generic drug manufacturers to challenge existing patents. This can lead to extensive and costly patent litigation.
• Patent Term Extensions (PTEs): In many jurisdictions, including the U.S., patent holders can apply for Patent Term Extensions to compensate for regulatory review delays. Acadia has likely sought and obtained PTEs for relevant patents.
• ANDA Filings: The filing of Abbreviated New Drug Applications (ANDAs) by generic competitors is a signal of potential future market entry. These filings often trigger patent litigation.

Impact on Market Exclusivity:

• Current Exclusivity (PDP): NUPLAZID benefits from strong market exclusivity for PDP, supported by its method of use patents and orphan drug designation. This has allowed Acadia to establish its market position and pricing.
• Dilemma for DRP Indication: If NUPLAZID is approved for DRP, the existing patent protection for PDP will not automatically extend to the new indication. Acadia will rely on patents that cover the use of pimavanserin for DRP. The strength and remaining life of these DRP-specific patents will be crucial for its exclusivity in this larger market.
• Generic Entry Timeline: The earliest anticipated generic entry for NUPLAZID for PDP indications is likely to be in the late 2020s, contingent on the outcomes of any patent litigation. If DRP is approved, the exclusivity for that indication will have its own distinct patent timeline.

Acadia's strategy involves actively defending its IP portfolio and seeking to extend market exclusivity for NUPLAZID through various patent mechanisms and litigation strategies.

What is the competitive landscape for NUPLAZID?

The competitive landscape for NUPLAZID is shaped by its approved indication for Parkinson's disease psychosis (PDP) and potential future indications, particularly dementia-related psychosis (DRP).

Current Competitive Landscape (PDP):

• Lack of Direct Competitors: As of the latest available data, NUPLAZID remains the only FDA-approved medication specifically for hallucinations and delusions associated with Parkinson's disease psychosis [1]. This grants it a dominant position in its approved niche.
• Off-Label Use of Antipsychotics: The primary "competition" in the PDP space comes from the off-label use of atypical antipsychotics. Historically, drugs like quetiapine, clozapine, and risperidone have been used, despite concerns that they can exacerbate motor symptoms in Parkinson's patients [5]. NUPLAZID's key differentiator is its mechanism of action, which avoids significant dopamine blockade and therefore does not worsen motor symptoms.
• Supportive Therapies: Non-pharmacological interventions and caregiver support are also part of the broader management landscape, though not direct drug competitors.

Emerging Competitive Landscape (DRP and Broader Psychosis):

The market for DRP, including Alzheimer's disease psychosis (ADP), represents a significantly larger patient population than PDP. Acadia's efforts to gain approval for NUPLAZID in DRP position it to compete in this burgeoning therapeutic area.

• Lecanemab (Leqembi) and Donanemab (Eli Lilly): These amyloid-beta targeting monoclonal antibodies are approved or seeking approval for Alzheimer's disease. While their primary indication is not psychosis, psychosis is a common symptom in Alzheimer's patients. The use of these drugs in conjunction with or in patients experiencing psychosis may influence treatment decisions. Their clinical trials have often included assessment of behavioral symptoms like hallucinations and agitation.
• Pimavanserin for DRP (Acadia's Efforts): Acadia has advanced NUPLAZID into late-stage clinical trials for DRP. If approved, it would be a direct competitor for managing psychosis in this patient group.
• Other Investigational Therapies: Several other compounds are in development for various forms of psychosis, including those associated with dementia. These could emerge as competitors in the coming years. Examples include other serotonin modulators or drugs targeting different neurotransmitter systems.
• Existing Antipsychotics (Off-Label for DRP): Similar to PDP, atypical antipsychotics are often used off-label for DRP. However, there are significant safety concerns with their use in elderly patients with dementia, including increased mortality risk [6]. This is a key area where NUPLAZID aims to provide a safer alternative.
• Antidepressants and Anxiolytics: In some cases, symptoms of agitation or mood disturbance in dementia may be treated with antidepressants or anxiolytics, though these are not direct treatments for psychosis.

Key Competitive Differentiators:

• Mechanism of Action: NUPLAZID's selective 5-HT2A inverse agonism is a key differentiator, particularly its lack of dopamine D2 receptor blockade, which avoids exacerbation of motor symptoms in Parkinson's disease. This is a significant advantage over traditional antipsychotics.
• Approved Indication: Being the first and only approved drug for PDP provides a strong market entry and physician trust.
• Safety Profile: While not without side effects, NUPLAZID's safety profile is considered favorable compared to conventional antipsychotics in vulnerable populations, especially regarding motor symptoms and potential for QTc prolongation [7].

The competitive landscape is dynamic. While NUPLAZID holds a unique position in PDP, its expansion into DRP will place it in a more crowded and evolving therapeutic area.

Key Takeaways

• NUPLAZID generated approximately $927 million in net sales in 2022, indicating substantial market penetration and consistent year-over-year growth.
• The drug's market is primarily driven by the unmet need for Parkinson's disease psychosis (PDP) treatment and the potential for expanded indications in dementia-related psychosis (DRP), a significantly larger patient population.
• Current U.S. list prices for NUPLAZID range from $1,000 to $1,300 per 30-day supply, with net prices lower due to rebates. Reimbursement is generally covered by commercial insurance and Medicare Part D, often with prior authorization.
• Price projections anticipate stable to modest increases (5-8% annually) in the short term. Mid-term pricing will face increasing pressure as U.S. patents approach expiration in the late 2020s. Significant price erosion (50-85%+) is expected in the long term (7-10 years) due to generic competition.
• Intellectual property, particularly method of use patents for PDP and any future DRP indications, is critical for maintaining market exclusivity. Patent litigation and generic challenges are anticipated as expiration dates approach.
• NUPLAZID is the sole approved treatment for PDP, differentiating itself from off-label atypical antipsychotics by not worsening motor symptoms. In the DRP space, it faces potential competition from emerging therapies and off-label use of existing drugs, with safety being a key competitive factor.

Frequently Asked Questions

1. What is the primary reason for NUPLAZID's current market dominance in Parkinson's disease psychosis? NUPLAZID is the first and only FDA-approved medication specifically for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Its unique mechanism of action, which does not block dopamine receptors, avoids exacerbating the motor symptoms characteristic of Parkinson's disease, a significant advantage over traditional antipsychotics.

2. How significant is the potential market expansion if NUPLAZID is approved for dementia-related psychosis (DRP)? The patient population for DRP is substantially larger than for PDP. Parkinson's disease affects approximately 1 million people in the U.S., with about 40% experiencing psychosis. Dementia, including Alzheimer's disease, affects millions more. Approval for DRP would open NUPLAZID to a much broader patient base, potentially more than doubling its addressable market.

3. What is the expected timeline for generic competition for NUPLAZID in the United States? Based on typical patent protection timelines for novel pharmaceuticals and industry reports, significant generic competition for NUPLAZID is anticipated to emerge in the late 2020s, contingent on the expiration and enforceability of its primary U.S. patents. The specific timing may vary depending on patent litigation outcomes.

4. Beyond price, what are the main competitive factors that will influence NUPLAZID's market share in the next decade? Key competitive factors include the success of NUPLAZID's label expansion for dementia-related psychosis, the safety and efficacy profile of any new entrants targeting similar indications, physician adoption rates for novel therapies, and the evolving reimbursement landscape for treatments of neurodegenerative and psychiatric conditions.

5. How does NUPLAZID's pricing strategy compare to traditional antipsychotics for psychosis? As a novel, first-in-class therapeutic with a unique mechanism of action and significant R&D investment, NUPLAZID is priced as a premium, branded specialty pharmaceutical. This typically places its per-day cost higher than older, generic antipsychotic medications that are used off-label for Parkinson's disease psychosis. Its pricing reflects its targeted indication and demonstrated clinical benefits in a population where other options are limited or detrimental.

Citations

[1] Acadia Pharmaceuticals Inc. (2023). Parkinson's Disease Psychosis. Retrieved from https://www.acadia.com/pipeline/parkinsons-disease-psychosis/

[2] World Health Organization. (2023). Parkinson disease fact sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/parkinson-disease

[3] Acadia Pharmaceuticals Inc. (2023). Investor Relations - Financial Information. (Data compiled from annual and quarterly reports).

[4] GoodRx. (2023). Nuplazid Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/nuplazid (Note: Prices are estimates and vary by pharmacy and location).

[5] Friedman, J. H. (2010). Psychosis in Parkinson's disease: the emerging role of pimavanserin. Current Treatment Options in Neurology, 12(4), 331-340.

[6] U.S. Food and Drug Administration. (2005). FDA Public Health Advisory: Antipsychotics in the Elderly. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-public-health-advisory-antipsychotics-elderly

[7] Acadia Pharmaceuticals Inc. (2023). NUPLAZID Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/205043s027lbl.pdf